Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Legal Issues Generic Drugs United States

Sun Pharma Challenges US Antitrust Ruling

Indian Firm Seeks Leave To Appeal Antitrust Judgement

  • News

Executive Summary

India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.

You may also be interested in...



Sun Denied Over US Antitrust Challenge

India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.

A Decade’s Deals In Indian Pharma Point To 2020 Trends

A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.

Sun Fights US Charges Over Delays

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Legal Issues Generic Drugs United States
Latest Headlines

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

UAE’s Bioventure Is Looking For Partners To Expand

Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

Medicines For Europe Highlights Industry Agenda

See All
UsernamePublicRestriction

Register

GB149509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By